- EBV Saliva study in collaboration with the Blizzard Institute, London, UK.
QSM Imaging study in collaboration with Weill Cornell Medical Center, NY.
NOW ENROLLING- PRIMARY PROGRESSIVE COHORT
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants with Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) (Sponsor: Genentech)
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in patients with Relapsing MS or Primary Progressive MS.
For more information, please contact Judy O’Connor/Jessica Siuta at 518-785-1000
RESEARCH LINE at 518-703-0695
Click here for more information from ClinicalTrials website
- Interested in participating in any of our clinical trials, please complete this Contact Form